Zolbetuximab/Chemo Up Front Yields Benefit in CLDN18.2+ Advanced Gastric/GEJ Cancer
January 20th 2023Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6.
PROpel Trial Data Show Boost in Radiographic PFS With Olaparib/Abiraterone for mCRPC
February 19th 2022Results of the phase 3 PROpel trial presented at 2022 ASCO GU indicate a benefit of olaparib-based therapy for patients with metastatic castration-resistant prostate cancer receiving treatment in the frontline setting.
Avelumab Maintenance Yields OS Improvement of First-Line in Advanced Urothelial Cancer
February 18th 2022Frontline avelumab plus best supportive care as maintenance showed an improvement in overall survival vs best supportive care alone in patients with advanced urothelial cancer treated after chemotherapy.
Link Established Between Active Disease/ICU Deferral and COVID-19 Mortality in AML, ALL, and MDS
December 12th 2021Investigators noted that patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were more likely to experience COVID-19 mortality vs non-cancer patients.
Treatment With Adjuvant Atezolizumab Yields Improved Outcomes in Stage II-IIIA PD-L1–Positive NSCLC
September 20th 2021Patients with stage II to IIIA non–small cell lung cancer experienced an improvement in disease-free survival and time to locoregional and distant relapse after being treated with adjuvant atezolizumab.